|
FY2026
12 months to Mar 31, 2026
|
FY2025
12 months to Mar 31, 2025
|
FY2024
12 months to Mar 31, 2024
|
FY2023
12 months to Mar 31, 2023
|
|
|---|---|---|---|---|
| EXPENSES | ||||
| Research | ||||
| General and administrative costs | ||||
| Share-based compensation | ||||
| TOTAL EXPENSES | ||||
| OTHER INCOME (EXPENSES) | ||||
| Interest income | ||||
| Change in fair value of investments measured at fair value through profit or loss | ||||
| Contingent consideration accretion | ||||
| Change in fair value of contingent consideration | ||||
| Foreign currency translation gain | ||||
| Other loss | ||||
| TOTAL OTHER INCOME | ||||
| Debt issuance cost | ||||
| Fair value loss on financial instruments | ||||
| TOTAL OTHER INCOME (LOSS) | ||||
| NET LOSS FOR THE YEAR | ||||
| OTHER COMPREHENSIVE INCOME (LOSS) | ||||
| Unrealized gain (loss) on translation of foreign operations | ||||
| COMPREHENSIVE LOSS FOR THE YEAR | ||||
| Basic loss per share for the year (in dollars per share) | ||||
| Diluted loss per share for the year (in dollars per share) | ||||
| Weighted average number of common shares outstanding - diluted (in shares) | ||||
| Weighted average number of common shares outstanding - basic (in shares) |
Loading...
